Array Biopharma Inc., of Boulder, Colo., said interim results from an ongoing combination trial of ARRY-520 with Kyprolis (carfilozomib) in patients with relapsed or refractory multiple myeloma (MM) who are refractory or intolerant to Velcade (bortezomib) were reported at the European Hematology Association meeting.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST